A detailed history of Bard Associates Inc transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Bard Associates Inc holds 312,399 shares of HBIO stock, worth $668,533. This represents 0.31% of its overall portfolio holdings.

Number of Shares
312,399
Previous 296,995 5.19%
Holding current value
$668,533
Previous $846,000 0.71%
% of portfolio
0.31%
Previous 0.35%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$2.64 - $3.54 $40,666 - $54,530
15,404 Added 5.19%
312,399 $840,000
Q2 2024

Aug 12, 2024

BUY
$2.77 - $4.63 $15,719 - $26,275
5,675 Added 1.95%
296,995 $846,000
Q1 2024

May 13, 2024

BUY
$4.02 - $5.39 $23,709 - $31,790
5,898 Added 2.07%
291,320 $1.24 Million
Q4 2023

Feb 13, 2024

SELL
$4.0 - $5.49 $2,000 - $2,745
-500 Reduced 0.17%
285,422 $1.53 Million
Q3 2023

Nov 13, 2023

SELL
$4.0 - $5.82 $4,000 - $5,820
-1,000 Reduced 0.35%
285,922 $1.23 Million
Q2 2023

Aug 11, 2023

SELL
$4.19 - $6.16 $18,331 - $26,950
-4,375 Reduced 1.5%
286,922 $1.58 Million
Q1 2023

May 12, 2023

SELL
$2.45 - $4.22 $4,900 - $8,440
-2,000 Reduced 0.68%
291,297 $1.22 Million
Q4 2022

Feb 10, 2023

SELL
$2.12 - $2.86 $10,600 - $14,300
-5,000 Reduced 1.68%
293,297 $812,000
Q3 2022

Nov 09, 2022

SELL
$2.33 - $3.92 $932 - $1,568
-400 Reduced 0.13%
298,297 $764,000
Q2 2022

Aug 11, 2022

BUY
$3.28 - $6.42 $27,880 - $54,570
8,500 Added 2.93%
298,697 $1.08 Million
Q4 2021

Feb 14, 2022

SELL
$6.37 - $8.18 $28,665 - $36,810
-4,500 Reduced 1.53%
290,197 $2.05 Million
Q2 2021

Aug 12, 2021

SELL
$5.44 - $8.4 $2,040 - $3,150
-375 Reduced 0.13%
294,697 $2.46 Million
Q1 2021

May 13, 2021

SELL
$3.91 - $6.99 $5,865 - $10,485
-1,500 Reduced 0.51%
295,072 $1.61 Million
Q4 2020

Feb 11, 2021

SELL
$3.0 - $4.5 $450 - $675
-150 Reduced 0.05%
296,572 $1.27 Million
Q3 2020

Nov 12, 2020

SELL
$2.75 - $4.2 $9,762 - $14,910
-3,550 Reduced 1.18%
296,722 $893,000
Q2 2020

Aug 13, 2020

SELL
$2.12 - $3.14 $26,500 - $39,250
-12,500 Reduced 4.0%
300,272 $931,000
Q1 2020

May 13, 2020

BUY
$1.42 - $3.29 $2,343 - $5,428
1,650 Added 0.53%
312,772 $691,000
Q4 2019

Feb 13, 2020

SELL
$2.45 - $3.25 $220,997 - $293,159
-90,203 Reduced 22.48%
311,122 $949,000
Q4 2019

Feb 13, 2020

BUY
$2.45 - $3.25 $219,037 - $290,559
89,403 Added 28.66%
401,325 $2.28 Million
Q3 2019

Nov 14, 2019

SELL
$1.59 - $3.47 $10,454 - $22,815
-6,575 Reduced 2.06%
311,922 $959,000
Q2 2019

Aug 13, 2019

SELL
$1.93 - $4.59 $337 - $803
-175 Reduced 0.05%
318,497 $637,000
Q1 2019

May 13, 2019

SELL
$2.77 - $4.38 $9,141 - $14,454
-3,300 Reduced 1.02%
318,672 $1.37 Million
Q4 2018

Feb 13, 2019

SELL
$3.03 - $5.0 $12,423 - $20,500
-4,100 Reduced 1.26%
321,972 $1.02 Million
Q3 2018

Nov 14, 2018

SELL
$5.0 - $6.65 $15,000 - $19,950
-3,000 Reduced 0.91%
326,072 $1.71 Million
Q2 2018

Aug 15, 2018

SELL
$4.2 - $5.95 $15,540 - $22,015
-3,700 Reduced 1.11%
329,072 $1.76 Million
Q1 2018

May 14, 2018

SELL
$3.3 - $5.15 $48,180 - $75,190
-14,600 Reduced 4.2%
332,772 $1.66 Million
Q4 2017

Feb 13, 2018

SELL
$3.08 - $3.8 $4,620 - $5,700
-1,500 Reduced 0.43%
347,372 $1.15 Million
Q3 2017

Nov 14, 2017

BUY
$2.7 - $3.75 $941,954 - $1.31 Million
348,872
348,872 $1.31 Million

Others Institutions Holding HBIO

About HARVARD BIOSCIENCE INC


  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $89.1M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track This Portfolio

Track Bard Associates Inc Portfolio

Follow Bard Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bard Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bard Associates Inc with notifications on news.